TY  - GEN
AU  - Klotz,Laurence H
AU  - McNeill,Irene Y
AU  - Kebabdjian,Marlene
AU  - Zhang,Liying
AU  - Chin,Joseph L
TI  - A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study
SN  - 1873-7560
PY  - 2013///0924
KW  - Absorptiometry, Photon
KW  - Administration, Oral
KW  - Aged
KW  - Aged, 80 and over
KW  - Alendronate
KW  - administration & dosage
KW  - Alkaline Phosphatase
KW  - blood
KW  - Analysis of Variance
KW  - Androgen Antagonists
KW  - Antineoplastic Agents, Hormonal
KW  - Biomarkers
KW  - Bone Density
KW  - drug effects
KW  - Bone Density Conservation Agents
KW  - Canada
KW  - Chi-Square Distribution
KW  - Collagen Type I
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Hip Joint
KW  - diagnostic imaging
KW  - Humans
KW  - Injections, Intramuscular
KW  - Leuprolide
KW  - Lumbar Vertebrae
KW  - Male
KW  - Middle Aged
KW  - Osteoporosis
KW  - Patient Selection
KW  - Peptides
KW  - Predictive Value of Tests
KW  - Prostatic Neoplasms
KW  - drug therapy
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.eururo.2012.09.007
ER  -